| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 1.3K | 20.9% |
| Total Income | 1.3K | 20.9% |
| Expenditure | 971.56 | 14.6% |
| PBT | 343.60 | 46.7% |
| Net Profit | 303.33 | 91.7% |
| OPM | 23.66% | 4.17pp |
| NPM | 23.83% | 8.81pp |
| EPS | 1.52 | 85.4% |
Incyte Reports Q1 2026 Revenue of $1.27 Billion, Up 21% Y-o-Y
03 May 2026 · 3 May, 6:27 pm
Summary
Incyte reported a strong start to 2026 with Q1 revenue reaching $1.27 billion, a 21% increase year-over-year. Total net sales increased by 20% to $1.10 billion, driven by demand for Jakafi, Opzelura, Niktimvo, Monjuvi, and Zynyz. The company is progressing its late-stage pipeline with 10 Phase 3 studies underway and anticipates four product approvals and launches over the next 12 months. Incyte reaffirmed its full year 2026 financial guidance.
Key Highlights
- 1
Incyte reported total revenue of $1.27 billion in Q1 2026, a 21% increase compared to Q1 2025.
- 2
Total net sales for Q1 2026 reached $1.10 billion, reflecting a 20% increase compared to the same period in 2025.
- 3
Jakafi net sales increased by 7% to $758 million compared to the first quarter of 2025.
- 4
Opzelura net sales increased by 20% to $143 million compared to the first quarter of 2025.
- 5
Hematology and Oncology portfolio net sales increased by 116% to $204 million compared to the first quarter of 2025.
- 6
The company anticipates four product approvals and launches from mid-2026 into early 2027.
- 7
GAAP net income was $303.33 million, or $1.47 per diluted share.
Management Comments
Bill Meury
“Our first quarter represented a strong start to 2026, driven by 20% year-over-year net sales growth and strong commercial execution. At the same time, we are making significant progress toward building a more durable, growth oriented portfolio with four anticipated product approvals and launches over the next 12 months, positive registrational data for povorcitinib in vitiligo and a late stage pipeline that now includes 10 Phase 3 studies underway, including the initiation of a pivotal trial of our G12D inhibitor in first line pancreatic ductal adenocarcinoma.”
Informational and educational content only. Not investment advice.